Ardent Health, Inc. 8-K Filing

FAQ

Key Financial Figures

• $50.0 million — y") issued a press release announcing a $50.0 million stock repurchase program. The full text

Filing Documents

• ardt-20251117.htm (8-K) — 33KB
• ex99-111825pressrelease.htm (EX-99) — 12KB
• ardtlogoa.jpg (GRAPHIC) — 50KB
• 0001628280-25-052879.txt ( ) — 234KB
• ardt-20251117.xsd (EX-101.SCH) — 2KB
• ardt-20251117_lab.xml (EX-101.LAB) — 22KB
• ardt-20251117_pre.xml (EX-101.PRE) — 13KB
• ardt-20251117_htm.xml (XML) — 3KB

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. On November 18, 2025, Ardent Health, Inc. (the "Company") issued a press release announcing a $50.0 million stock repurchase program. The full text of the press release is included as Exhibit 99 to this Current Report on Form 8-K (this "Form 8-K") and is incorporated by reference hereto. The information furnished with this Item 7.01, including Exhibit 99 , shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

03. Other Information

Item 2.03. Other Information. On November 17, 2025, the Company's Board of Directors authorized a stock repurchase program pursuant to which the Company may repurchase an aggregate of up to $50.0 million of the Company's common stock, $.01 par value per share ("Common Stock"). This program has no specified expiration date. The Company may make repurchases of its Common Stock through open market purchases, privately negotiated transactions, block trades or other transactions in accordance with applicable securities laws, subject to market conditions and other factors. Open market purchases will be structured to occur in accordance with applicable federal securities laws, including within the pricing and volume requirements of Rule 10b-18 under the Exchange Act. The Company may also enter into Rule 10b5-1 plans from time to time to facilitate repurchases of its Common Stock. The Company's repurchase program does not require the Company to acquire any specific number or amount of Common Stock and may be modified, suspended or terminated at any time. The Company expects to fund repurchases with existing cash and cash equivalents and ongoing cash from operations. Item9.01. Financial Statements and Exhibits. (d) Exhibits: Exhibit No. Exhibit Description 99 Press release issued on No vember 18, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: November 18, 2025 ARDENT HEALTH, INC. By: /s/ Stephen C. Petrovich Name: Stephen C. Petrovich Title: Executive Vice President & General Counsel

View Full Filing

View this 8-K filing on SEC EDGAR